Investigation of Diagnostic Improvement Gained Through Optimization of MR Methods for Breast Cancer Detection

Breast Neoplasms Clinical Trial

— BCD  

Official title:

Investigation of Diagnostic Improvement Gained Through Optimization of MR Methods for Breast Cancer Detection

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02411760
• Other study ID #: STU 052014-042
• Status: Completed
• Phase: N/A
• First received: February 27, 2015
• Last updated: October 17, 2017
• Start date: May 2014
• Est. completion date: May 2017

Study information

• Verified date: October 2017
• Source: University of Texas Southwestern Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

In a single MRI exam on a research scanner, each lesion will be categorized using the BI-RADS MRI score, which utilizes the DCE data alone, and then again using a modified BI-RADS score, which utilizes both DWI and DCE data. The sensitivity and specificity of each approach will be determined using pathology as the gold standard.

Description:

MR examinations will be performed on a 3.0 Tesla GE whole-body scanner using an elliptically driven body coil for transmit and a multi-channel bilateral breast coil for receive. The multi-channel coil will consist of 8, 16 or 31 channels. DCE-MRI: DCE-MRI will be carried out using a three-dimensional (3D) turbo fast lowangle gradient echo sequence (TFE) combined with parallel acquisition Sensitivity Encoding (SENSE) technique. The imaging plane will be set in axial plane so that both breasts are included in the images. One image will be acquired before and four images will be acquired after intravenous administration of a standard dose of 0.1 mmol per kg of body weight of Gadavist (Schering AG, Germany) at a rate of 3ml/sec. with subjects in the prone position, breathing normally during the scan. The total scan time for the DCEMRI will be about 8 minutes.

Pharmacokinetic parameters, including the volume transfer constant Ktrans, the fractional volume of extravascular extracellular space of the target tissue ve, and the rate constant kep, will be estimated by fitting a pharmacokinetic model to the time-intensity curves obtained from the DCE-MRI. In this study, the concentration of tracer Ct(t) after bolus injection is assumed to obey the model proposed by Tofts and Kermode (20). DWI-MRI examinations: The DWI acquisition will occur before and/or after contrast enhancement used in DCE imaging. Immediately after the completion of imaging with the 16 (or 31) channel breast coil, the patient will be repositioned replacing the breast coil with an 8 channel breast coil and additional DWI acquisitions will be made. Data for apparent diffusion coefficient assessment on diffusion-weighted imaging will be acquired using a single-shot Echo Planar Imaging sequence in the transverse plane. The DWI protocol will acquire images with up to 16 different b values. Slice dependent shimming will be performed to provide the maximum B0 homogeneity for each slice. The total scan time for the DWI-MRI will be about 5 minutes.

All of the DWI image data from the MRI examinations will be stored on a dedicated HIPPA compliant computer workstation (located in room NE6.114) for analysis. The relevant parameters will be mean ADC and the histogram of ADC in the lesions.

Conductivity imaging: A B1 map and a spin echo image will be acquired for measuring tissue conductivity (21).

The images used for conductivity measurement will be anonymized and sent to the manufacturer for further development of post-processing techniques.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 60
• Est. completion date: May 2017
• Est. primary completion date: May 2017
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Women with Breast Imaging-Reporting and Data System (BI-RADS) 4 or 5 Age = 18 years Ability to understand and the willingness to sign a written informed consent.

Exclusion Criteria:

Subjects who have had a needle biopsy of the suspicious area within the last 6 weeks Subjects who have contraindication to contrast enhanced MRI examination.

Contraindications to MRI examinations include:

Medically unstable

• Heart failure

• Unstable angina

• Child bearing

• Lactating Any contraindication per MRI Screening Form (Appendix A attached).

• Implants contraindicated at 3T, pacemakers

• Poorly controlled diabetes

• Body weight greater than 300 pounds

• Claustrophobic Since each patient is receiving a gadolinium based contrast agent intravenously:

• eGFR < 60 mL/min/1.73m2

• Sickle cell disease

• Hemolytic anemia

Subjects must not be pregnant or nursing due to the potential for gadolinium contrast agents to harm fetuses or nursing infants.

Related Conditions & MeSH terms

• Breast Neoplasms

Intervention

Procedure:
• 3 Tesla Magnetic Resonance Imaging
Assessment of the performance of DWI/ADC measurements alone, and as an adjunct to dynamic contrast enhanced (DCE) MRI in diagnosing/characterizing breast cancer.

Locations

Country	Name	City	State
United States	UT Southwestern Medical Center - Advanced Imaging Research Center	Dallas	Texas

Sponsors (1)

Lead Sponsor	Collaborator
University of Texas Southwestern Medical Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Diagnostic Improvement Gained using an optimized MR Method for Breast Cancer Detection.	The sensitivity and specificity of breast cancer detection using ADC maps acquired with a 31 channel breast coil and improved B0 shimming will be compared to the sensitivity and specificity of cancer detection using DCE MRI.	Each of 60 patients will have 1 60 minute scan prior to biopsy